{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.75","upperLimit":"72.43","value":"63.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"}],"units":"Participants"}],"title":"IRC Assessment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.16","upperLimit":"77.11","value":"69.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"}],"units":"Participants"}],"title":"Investigator Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"}],"units":"Participants"}],"description":"The disease control rate (DCR) was defined as the percentage of participants achieving CR, PR, or SD that lasted for at least 16 weeks. Tumor response was assessed by the investigator and IRC according to RECIST v1.1. CR: disappearance of all target, non-target lesions; normalization of tumor marker level; and reduction in all lymph nodes size to \\<10 mm. PR: \\>/=30% decrease in the SoD of target lesions (taking as reference the baseline SoD). PD: \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SoD, taking as reference the smallest SoD recorded since treatment started; 1 or more new lesion(s); and/or unequivocal progression of non-target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SoD while on study. The 95% CI was computed using Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on RE population which included all participants with measurable disease at baseline, who had baseline tumor assessment, and who received at least one dose of alectinib. Here, 'Number Analyzed'=number of participant evaluable for specified category.","reportingStatus":"POSTED","timeFrame":"Baseline; assessments every 8 weeks post-baseline until progressive disease, unacceptable toxicity, consent withdrawal, death, other reason deemed by investigator, or last tumor assessment (up to approximately 2.5 years)","title":"Percentage of Participants Achieving CR, PR or Stable Disease (SD) According to RECIST v1.1 in RE Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}